Poultry Diagnostic Market-By Technology (ELISA, PCR), By Disease Type,By Service Provider, and By Region-Prediction 2022-2031

SDKI Inc. published a new report on the poultry diagnostic market on January 25, 2022. This study includes the statistical and analytical approaches needed to grow the poultry diagnostic market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-53282

The poultry diagnostics market is estimated to reach a market value of US $ 418.6 million in 2022 and reach US $ 792.1 million by 2031, with a CAGR of 8.3% during the 2022-2031 forecast period. increase.

Details of the survey report

https://www.sdki.jp/press-details/poultry-diagnostic-market/629

The outbreak of poultry disease is a major factor in the significant growth of the poultry diagnostic market. In July 2019, Vietnam reported an outbreak of the highly pathogenic avian influenza H5N1 strain, according to data from the World Organization for Animal Health (OIE). According to this data, the virus affected more than 1,140 birds and killed 300 birds. In addition, an outbreak of the H5N8 influenza virus was recently observed in June 2019. These outbreaks have led to a surge in demand for diagnostic services around the world.

As a result, businesses and private organizations are actively working to develop effective solutions for treating poultry diseases. In addition, technological advances have contributed to the growth of the poultry diagnostics market during the forecast period. BioChek provides a sensitive and specific PCR test kit that enables simultaneous detection of Newcastle disease virus in poultry extracts. However, farmers are hesitant to invest in poultry production due to the risks of natural disasters, disease outbreaks and economic uncertainty. This may curb the growth of the poultry diagnostic market during the forecast period.

Poultry diagnostic market segment

The poultry diagnostic market is by technology (ELISA, PCR), by disease type (Newcastle disease, bird salmonellosis, infectious bronchitis, bird flu, bird pasteurellosis, bird mycoplasmosis, infectious bursal disease, bird brain spinal cord). It is divided by flame), service provider (public, private), and region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Based on technology, the poultry diagnostic market is divided into enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and more. In 2019, the ELISA segment gained more than 50% revenue share in the global poultry diagnostics market. This test can be used to evaluate vaccination and diagnose poultry disease.

Regional Overview of the Poultry Diagnostic Market 

The North American region dominates the poultry diagnostic market during the 2022-2031 forecast period. The presence of multinational companies, an extensive distribution network, and advanced infrastructure for the veterinary drug industry have supported the growth of the poultry diagnostics market in the region. In this area, chickens are mainly bred on family-owned farms or poultry colonies. According to the United States Department of Agriculture's National Agricultural Statistics Bureau, there are approximately 233,770 poultry farms in the United States in 2012. This is driving the growth of the poultry diagnostic market in the region. Meanwhile, the Asia Pacific poultry diagnostic market is expected to witness significant growth during the forecast period. This is due to strict government regulations.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.

Leading Key Players

in the Poultry Diagnostic Market Key players in the poultry diagnostic market include Qiagen, BioChek, IDEXX Laboratories, Thermo Fischer and Zoetis. The survey includes a detailed competitive analysis of these major companies in the poultry diagnostics market, corporate profiles, recent developments, and key market strategies.

Report sample URL

https://www.sdki.jp/sample-request-53282

SDKI Inc. Company profile

SDKI Inc.'s goal is to uncover market scenarios for different countries such as Japan, China, the United States, Canada, the United Kingdom and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

Read More

Pulmonary arterial hypertension (PAH) market-by drug class, and by region-forecast 2022-2031

SDKI Inc. published a new research report on "Pulmonary Arterial Hypertension (PAH) Market-Forecast 2022-2031" on January 25, 2022. The report provides a complete assessment of the market and its growth prospects, along with new business opportunities in the industry. It also includes market size and annual growth during the 2022-2031 forecast period.

Report sample URL
https://www.sdki.jp/sample-request-53279

The pulmonary arterial hypertension (PAH) market is estimated to reach US $ 11.60 billion by 2031, from a market value of US $ 7.15 billion in 2022, growing at a CAGR of 5.6% during the 2022-2031 forecast period. Is expected.

Details of the survey report

https://www.sdki.jp/press-details/pulmonary-arterial-hypertension-pah-market/630

Pulmonary arterial hypertension is a debilitating condition, with increased pulmonary vascular resistance and pulmonary arteries. Characterized by pressure. This condition can lead to damage to the right ventricle or death of the patient. PAH may be associated with conditions such as hereditary, idiopathic, or congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAHs are classified as underestimated because the prevalence of this disorder is very low, with an estimated prevalence of approximately 15-50 cases per million people. However, the prevalence of this disorder has increased over the past few years due to risk factors such as smoking, tobacco consumption, sedentary lifestyles, and other idiopathic conditions.

The growth of the pulmonary arterial hypertension market is driven primarily by the government's favorable initiative for the development of orphan drugs. The government benefits in terms of enhanced patent protection, tax incentives, and more. The Orphan Drug Act of 2002 and the Orphan Drug Act of 1983 (ODA) are two important laws that promote the distribution and ethical use of orphan drugs. ODA promotes tax credits of up to 50.0% of overall research funding, protocol support, US FDA fee exemptions, and clinical tax incentives. This factor encourages key players to invest in this industry and significantly drives the growth of the pulmonary arterial hypertension (PAH) market.

Pulmonary arterial hypertension (PAH) market segment

The pulmonary arterial hypertension (PAH) market is divided by drug class (prostacyclin and analogs, SGC stimulants, ERA and phosphodiesterase-5), and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional Overview of the Pulmonary Arterial Hypertension (PAH) Market

In addition, the report covers all regions of the world, divided into North America, Europe, Asia Pacific, Latin America, the Middle East / Africa and more. The North American region has the largest share of the global pulmonary arterial hypertension (PAH) market. This is due to the medical infrastructure developed in the United States that facilitates access to advanced therapies. In addition, heightened awareness, high diagnostic rates, and government-backed initiatives are driving the growth of the region's pulmonary arterial hypertension (PAH) market during the forecast period. A well-planned redemption structure and high awareness have resulted in excellent diagnostic rates.

For further analysis, each region is further subdivided into countries:

· Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, and other Asia Pacific)

· North America (US and Canada)

· Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa)

· Latin America (Brazil, Mexico, Argentina, and others) Latin America)

· Leading player in the pulmonary arterial hypertension (PAH) market in Europe (UK, Germany, France, Italy, Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) Pulmonary arterial

lung Key players in the hypertension (PAH) market include Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer and Merck. The study includes a detailed competitive analysis of these leading companies in the pulmonary arterial hypertension (PAH) market, corporate profiles, recent developments, and key market strategies.

Sample URL of the report

https://www.sdki.jp/sample-request-53279

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

Read More

Revenue Cycle Management (RCM) Market-By Type (Integrated and Standalone), By Product Type (Software and Services), By Delivery Mode, By End-Use, and By Region-Forecast 2022-2031

SDKI Inc. published a new report on the Revenue Cycle Management (RCM) Market-Forecast 2022-2031 on January 25, 2022. This study includes the statistical and analytical approaches needed to grow the Revenue Cycle Management (RCM) market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-53281

The revenue cycle management (RCM) market is estimated to grow from a market value of US $ 78.59 billion in 2022 to US $ 189.10 billion by 2031, with a CAGR of 11.6% during the 2022-2031 forecast period. It has been.

Details of the survey report

https://www.sdki.jp/press-details/revenue-cycle-management-rcm-market/631

Revenue cycle management includes medical billing, appointment scheduling, patient enrollment tracking, Software used for medical activities such as tracking final payments. The main purpose of implementing this system in healthcare institutions is to develop effective policies and processes that enable organizations to remain financially sound. The RCM system combines the clinical and business parts of the medical sector. Therefore, it combines management data such as insurance company details and patient names with treatment types.

Favorable government policies play an important role in driving demand for revenue cycle management. The Affordable Care Act (ACA), which is in force in the United States, focuses on expanding the coverage of personal health insurance. The law aims to improve the quality of medical services and reduce the cost of care. Expanding insurance coverage is expected to increase the number of refunds and denials that need to be managed through RCM. In addition, increasing medical costs will increase the number of medical facilities. Therefore, there is a growing demand for solutions such as revenue cycle management systems for managing healthcare services.

However, the lack of skilled professionals who can effectively manage this system can curb the growth of the revenue cycle management (RCM) market.

Revenue Cycle Management (RCM) Market Segment

The Revenue Cycle Management (RCM) market is by type (integrated and stand-alone), product type (software and services), delivery mode (on-premises, web-based, cloud-based), end-use (diagnostic laboratory, doctor's office). Etc.), and divided by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional Overview of the Revenue Cycle Management (RCM) Market 

The Revenue Cycle Management (RCM) market is further subdivided based on region and is evaluated for market growth in each country. These include North America (US, Canada, and other North America), Europe (Germany, France, Italy, Spain, UK, and other Europe), Asia Pacific (China, Japan, India, Australia, Singapore, and others). Asia Pacific) and other regions.

Overall, North America and Europe have the largest share of the global revenue cycle management (RCM) market. In 2019, these regions generated US $ 18.3 billion. This is due to the high adoption of revenue cycle management services in the country of residence. In addition, federal agency support policies such as Medicare and the Medicaid EHR Incentive Program for the implementation of RCM systems are also contributing to the growth of the region's Revenue Cycle Management (RCM) market. Meanwhile, the Asia Pacific Revenue Cycle Management (RCM) market is growing at the highest CAGR during the forecast period.

A key player in the revenue cycle management (RCM) market

Key players in the revenue cycle management (RCM) market include Cerner Corporation, NextGen Healthcare, EPIC Systems, eClinicalWorks and Quest Diagnostics. This study includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these key companies in the Revenue Cycle Management (RCM) market.

Sample URL for the report

https://www.sdki.jp/sample-request-53281

SDKI Inc. Company Profile

SDKI Inc.'s goal is to market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. SDKI has gained trust and a customer base in more than 30 countries and is further focused on expanding its foothold in other pristine economies.

Read More

Smart Healthcare Market-By Product, and By Region-Forecast 2022-2031

SDKI Inc. published a new report on the smart healthcare market on January 25, 2022. The study includes the statistical and analytical approaches needed to grow the smart healthcare market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-53284

The smart healthcare market is estimated to grow from a market value of US $ 201.93 billion in 2022 to US $ 85.75 billion by 2031, with a CAGR of 19.8% during the 2022-2031 forecast period. ..

Details of the survey report

https://www.sdki.jp/press-details/smart-healthcare-market/632

With the acceptance of advanced digital and mobile technologies, for effective diagnosis of various chronic disease states The range of smart solutions in the medical industry was born. Smart health care not only cures the illness, but also confronts it at the right time. Incorporating the Internet of Things (IoT) and sensor technology into medical products has enabled patients to store health data and analyze it by professionals to better diagnose and result in illness. A smart wearable device is a device that patients can use to assess their fitness regime and health without professional guidance.

Increasing Internet of Things penetration is a key driver of the growth of the smart healthcare market during the forecast period. In addition, the rapid increase in mHealth adoption, the increasing government initiative to digitize healthcare, and the increased prevalence of chronic diseases will contribute to the growth of the smart healthcare market between 2022 and 2031. .. In addition, the aging population, favorable redemption schemes, and the increasing number of companies investing in the industry are creating growth opportunities for the smart healthcare market. However, low penetration of smart healthcare in developing regions such as the Middle East and Africa could curb growth in the smart healthcare market during the forecast period.

Smart healthcare market segment

The smart healthcare market is divided by product (RFID smart cabinets, RFID kanban systems, telemedicine, EHR, and mHealth) and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional Overview of the Smart Healthcare Market 

The North American region is leading the smart healthcare market during the forecast period. This is due to the growing government policy on the deployment of digital health and the availability of highly digital literacy infrastructure. In addition, the presence of key market participants, increased awareness of connected health care, and high penetration of the Internet and smartphones are also driving the growth of the smart healthcare market in the region. Meanwhile, the Asia Pacific region is expected to grow at a significant rate of growth between 2022 and 2031. This is due to a well-developed healthcare IT infrastructure and increased investment in smart healthcare.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.

Key Players in the Smart Healthcare Market 

Key players in the smart healthcare market include Olympus Corporation, Stanley Innerspace, GE, Siemens and Samsung. The survey includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these key companies in the smart healthcare market.

Sample URL for the report

https://www.sdki.jp/sample-request-53284

SDKI Inc. Company Profile

SDKI Inc.'s goal is to market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

Read More

Transcriptomics Technology Market-By Replacement Therapy , Route of Administration, Disease, and Region-Prediction 2022-2031

SDKI Inc. published a new report on the Transcriptomics Technology Market-Forecast 2022-2031 on January 25, 2022. This study includes the statistical and analytical approaches needed to grow the transcriptomics technology market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-53283

The transcriptomics technology market is estimated to grow from a market value of US $ 2.99 billion in 2022 to US $ 4.59 billion by 2031, with a CAGR of 5.5% during the 2022-2031 forecast period. increase.

Details of the research report

https://www.sdki.jp/press-details/transcriptomics-technology-market/633

Transcriptomics is an RNA transcript produced by the genome in a specific cell body under specific conditions. Is defined as a study of. These transcriptomics datasets typically require quantitative measurements of thousands of genes and are therefore created by a variety of high-throughput techniques such as next-generation sequencing and microarray analysis. The main purpose behind transcriptome analysis is to identify the genes that are differentially expressed and to better understand the pathology.

The growth of the transcriptomics technology market is driven primarily by ongoing technology upgrades, increasing demand for more compact and reliable products, and the introduction of robust and efficient methodologies. Affymetrix, Inc. introduced the GeneChip microarray in 1993 and has been working on continuous product changes to achieve higher efficiency. In addition, the growing demand for personalized medicine secures potential opportunities for commercialization of transcriptome research results. It is driving the growth of the transcriptomics technology market during the forecast period.

However, the lack of skilled talent and efficient data tools can curb the growth of the transcriptomics technology market during the forecast period.

Transcriptomics Technology Market Segment

The transcriptomics technology market is divided by replacement therapy (estrogen, human growth hormone, testosterone and thyroid), route of administration, disease, and region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional Overview of the Transcriptomics Technology Market 

The transcriptomics technology market is further subdivided based on region and is evaluated for market growth in each country. These include North America (US, Canada, and other North America), Europe (Germany, France, Italy, Spain, UK, and other Europe), Asia Pacific (China, Japan, India, Australia, Singapore, and others). Asia Pacific) and other regions.

The North American region, especially the United States, holds the largest share of the global transcriptomics technology market. Increased opportunities, increased health care costs, and the introduction of favorable government initiatives are key drivers of the growth of the transcriptomics technology market in the region. Meanwhile, the Asia Pacific transcriptomics technology market is expected to grow at a significant rate. This is due to the increasing number of key players preparing to invest new investments.

A major key player in the transcriptomics technology market

Key players in the transcriptomics technology market include Life Technologies Corporation, Illumina, Inc., F.Hoffmann-LaRoche Ltd., Agilent Technologies, Inc., Affymetrix, Inc. The survey includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these key companies in the transcriptomics technology market.

Sample URL for the report

https://www.sdki.jp/sample-request-53283

SDKI Inc. Company Profile

SDKI Inc.'s goal is to market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

Read More

White Biotechnology Market-By Product, By Application, and By Region-Forecast 2022-2031

SDKI Inc. published a new research report on "White Biotechnology Market-Forecast 2022-2031" on January 25, 2022. The report provides a complete assessment of the market and its growth prospects, along with new business opportunities in the industry. It also includes market size and annual growth during the 2022-2031 forecast period.

Report sample URL
https://www.sdki.jp/sample-request-53276

The white biotechnology market is estimated to grow from a market value of US $ 30.81 billion in 2022 to US $ 610.82 billion by 2031, with a CAGR of 8.9% during the 2022-2031 forecast period. ..

Details of the research report

https://www.sdki.jp/press-details/white-biotechnology-market/634

The industrial application of biotechnology has many potentials for sustainable development. The field of biotechnology that uses live cells from enzymes, yeasts, plants, and bacteria to synthesize new products is called white biotechnology. These products require less energy consumption, are easier to disassemble, and require less manufacturing waste. Increasing acceptance of new technology trends such as bioprocess modeling and metabolic modeling is a major driver of growth in the white biotechnology market during the forecast period. In addition, growing awareness of the environmental and functional benefits of using biofuels in developed and developing countries is also contributing to the growth of the white biotechnology market.

In addition, factors such as rising demand for bioplastics, favorable government policies, constant research and innovation to develop effective and high-quality APIs, and cost savings in production processes will drive the growth of the white biotechnology market. It will expand significantly. Regulators are continually striving to improve the predictability and efficiency of future biotechnology products through constant efforts. Governments in the United States, China, Brazil, Southeast Asia, India, and European countries are implementing some favorable policies of tax cuts and financial incentives to promote the application of white biotechnology. This creates growth opportunities for the white biotechnology market during the forecast period.

White Biotechnology Market Segment

The white biotechnology market is by product (biomaterials, biofuels, industrial enzymes and biochemistry), by application (food and feed additives, bioenergy, pharmaceutical ingredients, personal care, and household products) and by region. It will be split. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Based on the product, the market is divided into biomaterials, biofuels, industrial enzymes, and biochemistry. The biofuels and biochemicals segment is the segment that produces the most revenue. In 2017, these segments gained more than 70% of the revenue share of the global white biotechnology market. In addition, the volatile prices of traditional fuels such as natural gas, natural oils and coal have created growth opportunities in these segments.

Regional Overview of the White Biotechnology Market

In addition, the report covers all regions of the world, divided into North America, Europe, Asia Pacific, Latin America, the Middle East / Africa and more. North America accounted for the largest revenue share of 35.23% in the global white biotechnology market in 2017. Functional efficiency, environmental sustainability, and easy availability of raw materials are key factors driving the growth of the white biotechnology market in the region. Meanwhile, the Asia Pacific region has recently emerged as a major player in the white biotechnology market. In recent years, many developing countries in the Asia-Pacific region (India, Thailand, Philippines, Colombia, Vietnam, etc.) have enforced forced biofuel mixing laws.

For more detailed analysis, each region is further divided into countries:

· Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, and other Asia Pacific)

· North America (US and Canada)

· Middle East and Africa (Israel, GCC [Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Other Middle East and Africa)

· Latin America (Brazil, Mexico, Argentina, Other Latin America)

· Europe (UK, Germany, France, Italy, Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) Key players in the white biotechnology market The

Key players in the white biotechnology market are BioAmber, Amyris, BASF, Codexis, Evolva, Deinove. , Novozymes, Metabolic Explorer, Solazyme, etc. The survey includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these major companies in the white biotechnology market.

Report sample URL

https://www.sdki.jp/sample-request-53276

SDKI Inc. Company profile

SDKI Inc.'s goal is to uncover market scenarios in different countries such as Japan, China, the United States, Canada, the United Kingdom and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. SDKI has gained trust and a customer base in more than 30 countries and is further focused on expanding its foothold in other pristine economies.

Read More

Antibiotic Market-By Inhibitor Type (Protein Synthesis, Cell Wall, DNA, RNA), By Drug Class , and By Region-Prediction 2022-2031

SDKI Inc. published a new report on the antibiotic market on January 25, 2022. This study includes the statistical and analytical approaches needed to grow the antibiotic market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-53290

The antibiotic market is estimated to reach US $ 87.36 billion by 2031, from a market value of US $ 52.39 billion in 2022, and is expected to grow at a CAGR of 6.6% during the 2022-2031 forecast period.

Details of the survey report

https://www.sdki.jp/press-details/antibiotic-market/618

The number of individuals suffering from chronic diseases is increasing all over the world. According to the World Health Organization (WHO), chronic illness accounts for more than 60% of all deaths. That is, 36 million of the 57 million deaths worldwide have died. Antibiotics are increasingly being used to manage infectious and chronic diseases such as asthma, cystic fibrosis, and COPD. As a result, as the incidence of chronic diseases increases, the demand for antibiotics is likely to increase for the treatment of these conditions.

In addition, numerous national and international initiatives aimed at financially encouraging antibiotic research and development activities are on the rise. Some of the major initiatives include the New Drug (ND4BB) program for bad bugs with the Innovative Drug Initiative (IMI) and the Joint Programming Initiative (JPIAMR) on Antimicrobial Resistance. These types of initiatives will support the growth of the antibiotic market during the forecast period. However, growing concern about antibiotic abuse could curb the growth of the antibiotic market during the forecast period.

Antibiotic Market Segment

The antibiotic market is divided by type of inhibitor (protein synthesis, cell wall, DNA, RNA), by drug class (fluoroquinolone, cephalosporin, penicillin, macrolide, carbapenem, aminoglycoside), and by region. Will be done. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Based on the type of inhibitor, the antibiotic market is divided into protein synthesis, cell walls, DNA, RNA, and other inhibitors. The cell wall segment has the highest market share in the overall market. In 2019, this segment has a 42% share of the overall market and is projected to dominate the antibiotic market. This drug class includes antibiotics such as penicillin, cephalosporins and carbapenem. These are one of the most important groups of antibiotics and show maximum activity against Gram-positive and Gram-negative bacteria. This is driving the growth of this segment.

Regional Overview of the Antibiotic Market

The Asia-Pacific region has the largest share of the antibiotic market. In 2019, the region gained a share of about 47% of the total market. The growing prevalence of infectious diseases and chronic diseases, as well as the growing interest of global players in investing in this market, is supporting the growth of the antibiotic market in the region. Meanwhile, the antibiotic markets in North America and Europe are expected to grow at a considerable rate during the forecast period. This growth is due to favorable reimbursement policies, increased demand for branded therapies, and increased R & D activity.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.

Key Players in the Antibiotic Market 

Key players in the antibiotic market include Novartis AG, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Bayer AG and AstraZeneca. The study includes a detailed competitive analysis of these major companies in the antibiotic market, corporate profiles, recent developments, and key market strategies.

Report sample URL

https://www.sdki.jp/sample-request-53290

SDKI Inc. Company profile

SDKI Inc.'s goal is to uncover market scenarios for different countries such as Japan, China, the United States, Canada, the United Kingdom and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

Read More